Multibagger Selection: Perplexity's picks
Perplexity picked RXRX, SOUN, ACHR, BBAI, CRSP with a twelve-month thesis, measured against SPY at each checkpoint.
| Experiment | Multibagger Selection |
|---|---|
| Model | Perplexity |
| Prompt version | multibagger-selection-v1 |
| Asked | |
| Horizon | 12-month |
| Benchmark | SPY |
| Status | Being measured |
The picks
| Rank | Symbol | Return | Confidence | vs benchmark | Called right |
|---|---|---|---|---|---|
| 1 | RXRX | — | 54% | — | — |
| 2 | SOUN | — | 50% | — | — |
| 3 | ACHR | — | 47% | — | — |
| 4 | BBAI | — | 44% | — | — |
| 5 | CRSP | — | 42% | — | — |
Checkpoints
| Checkpoint | Portfolio return | Return vs SPY | Best peak multiple | Picks reaching 2x |
|---|---|---|---|---|
| 1 week | +1.77% | +2.06% | 1.11x | 0 |
The model's market view
Small- and mid-cap multibagger candidates face a demanding environment: elevated long-term Treasury yields, volatile AI sentiment and selective risk appetite favor companies with funded runways, verifiable commercial or clinical catalysts, and credible paths to operating leverage. The strongest setups combine a recent fundamental inflection with a dated 12-month catalyst rather than relying on sector momentum.
Why each pick
RXRX
Recursion is a clinical-stage AI drug-discovery company with a strengthened funding position and multiple dated catalysts. On October 15, 2026, Sanofi optioned its first AI-discovered development candidate, triggering a $10 million milestone; Recursion also reported positive REC-4881 Phase 1b/2 data in familial adenomatous polyposis and early REC-1245 signals, while completing a $200 million oversubscribed follow-on offering. The reference price is the October 19 regular-session close.
SOUN
SoundHound combines rapid revenue growth with a defined profitability milestone. Analysts cited by TipRanks expect Q3 2026 revenue above $61 million, up more than 45% year over year, and management targets adjusted EBITDA break-even by the end of 2026. The September LivePerson acquisition adds enterprise customers, including 25 Fortune 100 companies, and creates a cross-selling opportunity into the OASYS platform. The reference price is an intraday market-capitalization quote from October 20.
ACHR
Archer Aviation offers an asymmetric regulatory-commercialization option: its Midnight eVTOL has entered FAA Type Certification Phase 4, and the company has a UAE launch framework targeting air-taxi operations in 2026, plus planned eIPP flights in Texas and Los Angeles later in 2026. With about $1.56 billion in cash as of June 30, 2026, it has an unusually long runway for a development-stage aerospace company. The reference price is an intraday quote from October 20.
BBAI
BigBear.ai has a government-analytics backlog of $270 million at the end of Q2 2026 and announced more than $225 million in contract awards since July across homeland security, defense, intelligence and federal civilian agencies. Its low absolute valuation and Q3 earnings date on October 27, 2026 create a near-term evidence point, but the company still needs to convert awards into profitable growth. The reference price is an intraday delayed quote from October 20.
CRSP
CRISPR Therapeutics is near the upper end of the permitted market-capitalization range but remains one of the strongest evidence-backed biotech upside candidates. CASGEVY, its approved CRISPR-based therapy, reportedly grew sales 78% sequentially in the latest cited period, while year-end clinical readouts provide dated catalysts. The reference price is an intraday quote from October 20.
Other models on the same run
| Model | Picks |
|---|---|
| Claude Sonnet 5.5 | AMBQ, ASPN, SILC, ETON, CDNA |
| Muse Spark 1.1 | LUNR, PL, SOUN, BKSY, EXTR |
| Gemini 3 Pro | ASTS, RKLB, SMR, LUNR, ACHR |
| Grok 4.5 | INOD, PGY, TMDX, SEZL, CALX |
| DeepSeek | INOD, OUST, AEVA, LAES, AREC |
| GPT-6 | ARDX, AMPX, FLNC, TMDX, SERV |
ForecastNest provides AI-generated market analysis and quantitative research for informational and educational purposes only. Nothing here constitutes financial, investment, legal, or tax advice.